{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:38:15Z","timestamp":1790818695340,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10,20]]},"DOI":"10.1093\/jnci\/djq362","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T21:28:24Z","timestamp":1287437304000},"page":"1547-1556","source":"Crossref","is-referenced-by-count":80,"title":["Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin\u2013Topotecan and Carboplatin\u2013Paclitaxel vs Carboplatin\u2013Paclitaxel"],"prefix":"10.1093","volume":"102","author":[{"given":"P.","family":"Hoskins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Katsaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ghatage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Grimshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Elit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mendiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"D'Hondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Germa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Brotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. A.","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,10,20]]},"reference":[{"issue":"1","key":"key\n\t\t\t\t20170702093952_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med."},{"issue":"9","key":"key\n\t\t\t\t20170702093952_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst."},{"issue":"17","key":"key\n\t\t\t\t20170702093952_bib3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst."},{"issue":"17","key":"key\n\t\t\t\t20170702093952_bib4","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol."},{"issue":"6","key":"key\n\t\t\t\t20170702093952_bib5","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol."},{"issue":"12","key":"key\n\t\t\t\t20170702093952_bib6","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol."},{"issue":"6","key":"key\n\t\t\t\t20170702093952_bib7","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol."},{"issue":"10","key":"key\n\t\t\t\t20170702093952_bib8","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20170702093952_bib9","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol."},{"issue":"2","key":"key\n\t\t\t\t20170702093952_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/gyno.2001.6179","article-title":"Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer","volume":"81","author":"Bolis","year":"2001","journal-title":"Gynecol Oncol."},{"issue":"24","key":"key\n\t\t\t\t20170702093952_bib11","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/JCO.2000.18.24.4038","article-title":"Phase II feasibility study of sequential douplets of cisplatin\/topotecan followed by paclitaxel\/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study","volume":"18","author":"Hoskins","year":"2000","journal-title":"J Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20170702093952_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"for the EORTC Study Group on Quality of Life. The EORTC QLQ-C30: A quality of life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"key\n\t\t\t\t20170702093952_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","article-title":"on behalf of the EORTC Quality of Life Group and the Scottish Gynaecological Cancer trials Group. Development of the European Organization of Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report","volume":"37","author":"Cull","year":"2001","journal-title":"Eur J Cancer."},{"issue":"3","key":"key\n\t\t\t\t20170702093952_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines)","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"issue":"18","key":"key\n\t\t\t\t20170702093952_bib15","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"key\n\t\t\t\t20170702093952_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2006.02.024","article-title":"Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer","volume":"103","author":"Markman","year":"2006","journal-title":"Gynecol Oncol."},{"issue":"3","key":"key\n\t\t\t\t20170702093952_bib17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.2000.5982","article-title":"Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients","volume":"79","author":"van Dalen","year":"2000","journal-title":"Gynecol Oncol."},{"key":"key\n\t\t\t\t20170702093952_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1201\/b14760-88","article-title":"Minimization procedure","volume-title":"Encyclopedia of Biopharmaceutical Statistics","author":"Tu","year":"2003"},{"issue":"9","key":"key\n\t\t\t\t20170702093952_bib19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20170702093952_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s002800050755","article-title":"In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems","volume":"41","author":"Romanelli","year":"1998","journal-title":"Cancer Chemother Pharmacol."},{"issue":"15","key":"key\n\t\t\t\t20170702093952_bib21","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J Natl Cancer Inst."},{"issue":"13","key":"key\n\t\t\t\t20170702093952_bib22","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","article-title":"Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: multicenter Italian trials in ovarian cancer (MITO-I) randomized study","volume":"22","author":"De Placido","year":"2004","journal-title":"J Clin Oncol."},{"issue":"18s","key":"key\n\t\t\t\t20170702093952_bib23","doi-asserted-by":"crossref","first-page":"A5003","DOI":"10.1200\/jco.2006.24.18_suppl.5003","article-title":"A multicenter, randomized phase III study comparing paclitaxel\/carboplatin (PC) versus topotecan\/paclitaxel\/carboplatin (TPC) in patients with stage III (residual tumor > 1 cm after primary surgery) and IV ovarian cancer (OC)","volume":"24","author":"Scarfone","year":"2006","journal-title":"J Clin Oncol."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/102\/20\/1547\/18085345\/djq362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T01:29:42Z","timestamp":1592011782000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djq362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,20]]},"references-count":23,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2010,10,20]]},"published-print":{"date-parts":[[2010,10,20]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djq362","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,20]]}}}